Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adjuvant Therapy
11%
Apolipoprotein E4 (APOE4)
10%
Attentional Processing
13%
Breast Cancer
34%
Breast Cancer Survivors
13%
Cancer Control
9%
Cancer Study
88%
Capecitabine
11%
Chemotherapy
28%
Circulating Tumor DNA (ctDNA)
9%
Cognitive Difficulties
10%
Cognitive Function
27%
COVID-19
19%
Deficit Accumulation
13%
Depressive Symptoms
11%
Early Breast Cancer
9%
Endocrine Therapy
11%
Executive Function
13%
Functional Assessment of Cancer Therapy
10%
Gene Expression Profiling
9%
Genotype
13%
Immunoscore
9%
Longitudinal Relationship
12%
Machine Learning
12%
Metastatic Breast Cancer
26%
Newly Diagnosed
8%
Nivolumab
11%
Non-cancer
39%
Older Breast Cancer Survivor
100%
Older Survivors
9%
Older Women
15%
Oncologists
13%
Perceived Cognitive Impairment
10%
Physical Activity
21%
Processing Speed
15%
Quality of Life
15%
Randomized Phase II Trial
11%
Sleep Disturbance
13%
Speed Function
11%
Survivors
69%
Systemic Therapy
17%
Taxanes
11%
Thinking with
94%
Triple-negative Breast Cancer
11%
Tumor
17%
Well-being
12%
Women with Breast Cancer
15%
Medicine and Dentistry
Adjuvant Therapy
5%
Alzheimer's Disease
5%
Area Deprivation
5%
Arm
6%
Biological Marker
6%
Breast Cancer
88%
Breast Imaging
5%
Cancer Therapy
10%
Capecitabine
11%
Chemotherapy
27%
Cognition
20%
Cognitive Decline
7%
Cognitive Defect
7%
Comorbidity
7%
COVID-19
11%
Decision Making
8%
Diseases
7%
Executive Function
8%
Functional Assessment
9%
Gene Expression Profiling
7%
Genetics
5%
Granulosa Cell Tumour
5%
Health Care Cost
5%
Homologous Recombination
5%
Hormone Therapy
26%
Interleukin 6
5%
Isoprenaline
5%
Malignant Neoplasm
54%
Medical Care
5%
Neoplasm
6%
Next Generation Sequencing
5%
Nivolumab
11%
Oncologist
12%
Oncology
6%
Physical Activity
9%
Pooled Analysis
5%
Prostate Cancer
5%
Quality of Life
11%
Real-World Evidence
5%
Recurrent Disease
9%
Retroperitoneum
5%
Systemic Therapy
13%
Triple Negative Breast Cancer
11%
Tumor
10%
Tumor Gene
5%